Diagnostic Criteria and Treatment of Phyllodes Tumors

Introduction to Phyllodes Tumors

Phyllodes tumors are rare fibroepithelial breast neoplasms classified into benign, borderline, and malignant subtypes based on histologic features, though no uniform agreement exists on exact criteria for subtype assignment, and surgical margin status is more important than subtype for predicting recurrence 1, 2

The National Comprehensive Cancer Network recommends that mean age at presentation is in the 40s, occurring in an older age distribution than fibroadenomas but younger than invasive ductal/lobular cancers 1, 2, 3
A rapidly enlarging, usually painless breast mass is the hallmark presentation 1, 2, 3
Patients with Li-Fraumeni syndrome (germline p53 mutation) have increased risk 1, 2, 3

Phyllodes tumors often appear identical to fibroadenomas on ultrasound and mammography, making preoperative distinction difficult 1, 2, 3
In the setting of a large (>2 cm) or rapidly enlarging clinical "fibroadenoma," excisional biopsy should be performed to pathologically exclude phyllodes tumor 1, 2, 3, 4

All phyllodes tumors (benign, borderline, and malignant) require surgical excision with tumor-free margins of ≥1 cm 1, 2, 3, 5, 6
Lumpectomy or partial mastectomy is the preferred surgical therapy 1, 2, 3, 5, 6
Total mastectomy is necessary ONLY if negative margins cannot be obtained with breast-conserving surgery 1, 2, 3, 5, 6
Surgical axillary staging or lymph node dissection is NOT necessary because phyllodes tumors rarely metastasize to axillary lymph nodes 1, 2, 3, 5, 6

Radiotherapy is NOT routinely recommended for all phyllodes tumors 6
Consider radiotherapy ONLY for borderline or malignant tumors >5 cm in size, infiltrative margins, cases where clear margins could not be achieved despite re-excision attempts, or local recurrence, especially if additional recurrence would create significant morbidity 6

Neither chemotherapy nor endocrine therapy has any proven role in phyllodes tumor treatment 1, 2, 3, 6
Although 58% contain ER and 75% contain PR, endocrine therapy does not reduce recurrence or death 1, 2, 3
No evidence shows adjuvant cytotoxic chemotherapy reduces recurrence or death 1, 2, 3

Re-excision with wide tumor-free surgical margins is recommended for local recurrence 1, 2, 3, 6
Consider postoperative radiation therapy if additional recurrence would create significant morbidity 6
Most distant recurrences occur in the lung and should be treated according to NCCN Guidelines for Soft Tissue Sarcoma 1, 2, 3

Immediate reconstruction should be avoided in borderline phyllodes with high-risk features 6
Delayed reconstruction is preferred after primary oncological management is completed and local recurrence risk has diminished 6

Histologic subtype is the only independent prognostic factor, with 5-year disease-free survival rates of 95.7% for benign, 73.7% for borderline, and 66.1% for malignant tumors 1, 2, 3
However, margin status is more important than subtype for predicting local recurrence 1, 2, 3

Do NOT rely on core needle biopsy or FNA to exclude phyllodes tumor in a rapidly growing or large breast mass 1, 2, 3
Do NOT perform routine axillary staging - this adds unnecessary morbidity without benefit 1, 2, 3, 5, 6
Do NOT use adjuvant chemotherapy or endocrine therapy - these have no proven efficacy 1, 2, 3, 6
Do NOT routinely recommend radiotherapy for all phyllodes tumors - reserve for high-risk cases only 6
Do NOT accept inadequate surgical margins - this is the most important factor for preventing local recurrence 1, 2, 3, 6

Borderline and malignant phyllodes tumors should be referred to specialist sarcoma centers for pathology review and multidisciplinary team discussion 6

Spindle cell-predominant phyllodes tumors may be misdiagnosed as sarcomatoid carcinoma or smooth muscle tumors, according to the College of American Pathologists, and the diagnostic challenge is particularly significant in core biopsies where the characteristic leaf-like architecture may not be sampled 7